The drug, odanacatib, limits risk of osteoporotic fractures. However, a late-stage study found postmenopausal women were at an increased risk of stroke when taking the drug. Merck said Friday the findings do not support additional development or regulatory approval.
More articles about supply chain:
Mylan coupled executive pay with high profit targets: 7 things to know
Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics for $624M
Roche seeks FDA approval for additional use of cancer drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
